Key figures for the Group - Fourth quarter (October – December)

• Sales of goods amounted to KSEK 3,539 (4,445).
• Gross profit amounted to KSEK 2,165 (2,563), corresponding to a gross margin of 61 (58) percent.
• Operating profit amounted to KSEK 998 (-26,749).
• Earnings per share amounted to SEK 0.0000001 (-0.005).

Key figures for the Group - Twelve months (January – December)

• Sales of goods amounted to KSEK 14,788 (26,891).
• Gross profit amounted to KSEK 9,953 (15,159), corresponding to a gross margin of 67 (56) percent.
• Operating loss amounted to KSEK -19,449 (-58,648).
• Earnings per share amounted to SEK -0.000003 (-0.0170).

Please note that the figures at Group level are not directly comparable with 2024 due to changes in the company structure.

Significant events

Fourth quarter

• Strategic distribution agreements are signed for the US, Canada, Mexico and the UK.
• The reorganisation plan, prepared within the framework of the company reorganisation, is published.
• A plan meeting for company reorganisation will be held on 27 November in Uppsala District Court.
• A first order under the newly signed distribution agreement is received.
• The reorganisation plan gains legal force and the reorganisation is concluded.

After the end of the period

• The prospectus is published in connection with the rights issue of units.
• The company provides a business update due to the completion of the reorganisation and ongoing rights issue.
• The company announces the outcome of the rights issue.

Comments by the President and CEO

After some time in the company as a board member and periodically more operational, I have now been given the opportunity to temporarily participate and lead the company until a permanent CEO is in place.

We have systematically implemented several purposeful changes over a long period of time to streamline the company's operations and be able to turn the page to lay the foundation for a new, stable and long-term business for Peptonic. Therefore, the focus in the last quarters has been to restructure the company and cut unnecessary costs so that we have a stable and sustainable base to build on.

The operations of the parent company now form the core of Peptonic after unprofitable subsidiaries and products were closed down and eliminated. We are fully focused on our proprietary portfolio of intimate care products and are rebuilding our strategy from there. The products are primarily sold under our own brand, VagiVital, but also through partners under their brands. This streamlining creates clarity – both internally and externally – and gives us better conditions to develop the business with higher efficiency and profitability.

Those of you who follow the company know that a lot has happened in the past year, with a clear focus on implementing the aforementioned changes. We have now created a more cost-effective organisation with shorter decision-making paths and greater ability to act. The next step is about growth.

In the coming period, we will intensify our work on geographical expansion. We see a clear potential to strengthen our presence in existing markets while gradually establishing ourselves in new ones, both through our own channels and through strategic partnerships. Our ambition is to build a scalable structure that enables international growth while maintaining cost control.

In parallel, we work with product development. We review needs and opportunities and develop new products that complement and broaden our offering in intimate care, with a focus on quality, innovation and sustainability. By continuously developing the portfolio, we create more revenue legs and strengthen our position in the value chain.

We are also working to renew our message and our marketing. With a clearer brand platform for VagiVital and a more data-driven marketing strategy, we will increase our visibility, improve the customer journey and create a stronger relationship with our end customers. The focus is on long-term sales, brand building and profitable growth.

The recruitment of a new CEO is ongoing in parallel with the review of the long-term strategy for building the new Peptonic. In the meantime, the focus is on marketing and sales with the current organization. Together with the rest of the Board of Directors and the company's employees, I work actively to implement new ideas and changes that strengthen the company for the next phase.

The company and I look forward to soon being able to share more information regarding Peptonic's strategy going forward. We are convinced that the measures we have now implemented, combined with new initiatives in expansion, product development and marketing, create good conditions for a stable and profitable future.

Daniel Rudeklint,

Interim VD

The interim report is available on the company's website: https://www.peptonicmedical.se/finansiell-information/

For further information, please contact:
Daniel Rudeklint, interim CEO Peptonic Medical AB

Email: daniel.rudeklint@peptonicmedical.se
Phone: +46 73 158 02 73

About Peptonic Medical AB                                

Peptonic Medical AB (publ) is a Swedish medical technology company that develops and sells clinically proven self-care products in intimate women's health. Under the brands VagiVital and Vernivia, the Company offers an over-the-counter portfolio of effective and gentle products that help women understand, treat and prevent common medical conditions in the genital area. Peptonic's growth strategy is based on geographic expansion, especially in the US and Europe, and on continuously strengthening the product portfolio through its own product development and strategic acquisitions.

The company is headquartered in Stockholm, Sweden, and has subsidiaries Peptonic Medical Inc. and Common Sense Marketing Inc. in the United States. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.